Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sugemalimab - CStone Pharmaceuticals/EQRx

Next Previous
Drug Profile

Sugemalimab - CStone Pharmaceuticals/EQRx

Alternative Names: Cejemly; CS-1001; Sugelimab; WBP-3155; Zegema; Zegemet; Zegemex; ZEJIEMEI

Latest Information Update: 25 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CStone Pharmaceuticals
  • Developer Bayer; CStone Pharmaceuticals; EQRx
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Adenocarcinoma; Extranodal NK-T-cell lymphoma; Non-small cell lung cancer; Squamous cell cancer
  • Phase III T-cell lymphoma
  • Phase II Hodgkin's disease
  • Phase I/II Liver cancer; Solid tumours
  • No development reported Small cell lung cancer

Most Recent Events

  • 22 Feb 2026 Registered for Non-small cell lung cancer (In adults, Monotherapy, Late-stage disease, Inoperable/Unresectable) in United Kingdom (IV)
  • 25 Nov 2025 Registered for Non-small cell lung cancer (Inoperable/Unresectable, Monotherapy, Late-stage disease) in Liechtenstein, Norway, Iceland, European Union (IV)
  • 25 Nov 2025 Registered for Non-small cell lung cancer (Late-stage disease, Monotherapy, First-line therapy, Inoperable/Unresectable) in European Union, Iceland, Liechtenstein, and Norway (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top